Psoriasis patients get a second chance with higher drug dose

NCT ID NCT01680159

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 20, 2026 · Updated 18 times

Summary

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis whose symptoms had returned after initially responding to the standard dose of Remicade. The goal was to see if the increased dose could again improve skin symptoms, as measured by the Psoriasis Area and Severity Index (PASI). The study was completed and focused on patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis, or psoriatic erythroderma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational site

Chugoku, Japan
Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Kanto, Japan
Investigational site

Kinki, Japan
Investigational site

Kyushu, Japan
Investigational site

Tōhoku, Japan

Conditions

Explore the condition pages connected to this study.

PLAQUE PSORIASIS PSORIATIC ARTHRITIS PSORIATIC ERYTHRODERMA PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED)